NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks.
In the past week, the Nordic biotech and healthcare stocks declined 3%. Cessatech increased 38%, while 2Curex declined 64% although none of the stocks reported any news. FluoGuide saw progress with FG001 in one of the largest cancer markets worldwide. Furthermore, Goldman Sachs and BNP Paribas initiated new price targets significantly higher than current share prices for multiple stocks.
Latest news for the Danish biotech companies
Acarix AB has developed a technology to identify heart diseases. Moving forward, product sales are the main driver for the stock.
Acarix released its annual report for 2024 with revenue in line with 2023, and major net losses at MSEK -66.
Ascendis Pharma develops so-called prodrugs, which are medications that start in an inactive form and become active once inside the body. The main stock price driver going forward is the development and commercialization of its TransCon technology.
No news the past week
Biosergen is developing BSG005 to treat serious and life-threatening fungal infections safely and with limited side effects, contrary to current drugs. The main price triggers are centered around product development and the ongoing clinical trials
No news in the past week
Cessatech develops pain treatments for children. The company is finalizing its phase 3 study for its lead candidate, and the main price driver will be the commercialization for this product.
No news in the past week
Curasight is focused on diagnosing (uTRACE) and treating cancer (uTREAT) through targeted radionuclide therapy. The benefit is treating cancer at the cellular level without harming healthy cells. The main driver of the stock moving forward is the financing of the portfolio as well as pipeline and partnership development. You can read our full investment case here (in Danish).
Curasight is in the process of an MDKK 100 capital raise. 47% of the rights issue is secured through pre-subscriptions and guarantee commitments. The subscription price will be set at 65% of the theoretical share price (based on 10-day volume-weighted average price) from the time of the board’s formal decision to carry out the issue at April 4. Therefore, the subscription price remains unknown. However, the price will not be lower than the nominal value per share or higher than DKK 10.24. At the time of writing, the share is trading at 6.10. The subscription period runs from May 2 through May 16. You can read more in Danish here.
DanCann Pharma focuses on discovering, developing, and producing medical cannabis for pain and neurological conditions. The stock price drivers are regulatory progress and sales development.
No news the past week
Evaxion Biotech develops personalized immunotherapies and vaccines, with recent advancements in their cancer vaccine candidate EVX-01. Clinical trial outcomes and technological innovations currently drive the stock price.
Evaxion will present at the World Vaccine Congress from April 21 to April 24.
ExpreS2ion provides protein production technologies for vaccine development and has its own pipeline. Key stock drivers include pipeline progression and licensing agreements.
ExpreS2ion signed a Letter of Intent with WuXi Vaccines to initiate a technology evaluation of ExpreS2ion’s proprietary Drosophila S2 expression technology platform for the bioproduction of vaccines and other biologics. The LOI aims to form a strategic collaboration in the next 12 months following successful feasibility testing of the ExpreS2 system in a client project of Wuxi Vaccines.
Fluoguide develops tumor-targeted products that make cancer visible on imaging solutions to improve cancer surgery outcomes, especially within brain and head & neck cancer surgery. The main stock driver is the clinical validation of their imaging technology and additional partnerships.
FluoGuide announced enrollment of the first patient in its phase II study with FG001 in head and neck cancer. Head and neck cancer is the 6th most common cancer worldwide, and approximately 450,000 patients die annually.
Genmab focuses on creating differentiated antibody therapeutics for the treatment of lymphatic leukemia and solid tumors. Genmab has developed Darzalex, with sales of nearly USD 12 billion in 2024. The stock performance is primarily driven by product sales and pipeline developments.
Genmab announced the sales numbers for Darzalex in the first quarter of 2025 at USD 3.2 billion, surpassing expectations of USD 3.1 billion. Afterwards, the company received new price targets by Goldman Sachs and BNP Paribas at DKK 1,764 and 1,300, respectively.
Gubra offers preclinical contract research services and develops treatments for metabolic diseases. Key stock drivers are partnerships and progress in their internal drug pipeline.
No news the past week
Initiator Pharma develops treatments for erectile dysfunction and neuropathic pain. The main stock catalyst is the outcome of clinical trials.
No news the past week
IO Biotech is developing immune-modulating therapies for cancer, with a focus on conditions like melanoma. Stock performance is driven by clinical trial advancements.
No news the past week
Pila Pharma is working on TRPV1 antagonists aimed at treating type 2 diabetes. Early clinical data and funding developments are key stock drivers.
No news the past week
Saniona focuses on ion channel-targeted therapies, including rare eating disorders. The main stock driver is the progression of their clinical pipeline and the approval of the weight loss drug Tesofensine in Mexico.
No news the past week
Scandion Oncology is developing treatments to overcome chemotherapy resistance in cancer patients. The company has recently faced significant financial challenges, thus, financial stability is the main driver for the stock price.
No news in the past week
SynAct Pharma develops drugs targeting inflammatory diseases through melanocortin pathways. Clinical milestones significantly influence stock performance
SynAct Pharma announced they will participate at the BIO International Convention in Boston, from June 16-19.
ViroGates provides prognostic products for acute care settings to improve patient triage. Stock drivers include hospital adoption rates and revenue growth.
No news the past week
Y-mAbs Therapeutics develops antibody-based therapies for pediatric cancers. Stock performance is driven by regulatory approvals and commercialization efforts.
No news the past week
Zealand Pharma specializes in peptide-based treatments for metabolic and gastrointestinal diseases. The stock has seen increased awareness following the obesity hype, and advancements in their late-stage pipeline and partnerships are key stock price influencers.
Goldman Sachs lowered its price target from DKK 980 to DKK 873. This comes two weeks after they increased it to DKK 980 from DKK 973. The current price is DKK 396.
2cureX offers the IndiTreat platform for individualized cancer treatment testing. The main stock driver is the adoption of their technology by hospitals and subsequent sales growth.
No news the past week
The latest share price developments for the Danish biotech stocks
On average, the Danish biotech and healthcare stocks declined 3%. Cessatech and 2cureX stand out in each end with returns of 38% and -64%, although none of the companies posted any news. Cessatech is climbing even higher today with a 22% increase, which is not accounted for in the table below. Genmab rose slightly after sales numbers for Darzalex beat expectations and new price targets were initiated. On the other hand, Fluoguide declined 2%, although they announced the enrollment of the first patient in a phase II study in head and neck cancer, and ExpreS2ion declined 3% following a LOI with Wuxi Vaccines regarding technology evaluation of its Drosophila S2 expression technology platform for the bioproduction of vaccines and other biologics. Finally, Goldman Sachs lowered their price target for Zealand Pharma, but continues to see great potential.
Overview of share price development in the past week, year-to-date, and the last twelve months
DanCann Pharma does not appear on the list due to data issues.
AcouSort is raising capital, and you can participate!
AcouSort AB is a Danish-led medtech company that develops automated solutions for handling biological samples, such as blood samples for diagnostics and patient treatment. AcouSort has already developed several research instruments and is raising 34.1 MSEK to establish an OEM partnership. 73% of the issue is secured, and the subscription period runs until May 5, 2025. You can read more about AcouSort and other rights issues at Nyemission.dk (in Danish)
